Number of the records: 1  

Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors

  1. 1.
    0374499 - ÚJF 2012 RIV GB eng J - Journal Article
    Beckford, Denis R. - Eigner, Sebastian - Eigner-Henke, Kateřina - Lebeda, Ondřej - Melichar, František - Beran, Miloš
    Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
    Nuclear Medicine and Biology. Roč. 39, č. 1 (2012), s. 3-13. ISSN 0969-8051. E-ISSN 1872-9614
    R&D Projects: GA MŠMT 2B06165
    Institutional research plan: CEZ:AV0Z10480505
    Keywords : Radioimmunotherapy * Nimotuzumab * (177)Lu * Monoclonal antibody
    Subject RIV: FR - Pharmacology ; Medidal Chemistry
    Impact factor: 2.517, year: 2012

    Objectives: Nimotuzumab (h-R3) is a humanized monoclonal antibody (mAb) which recognizes the external domain of the epidermal growth factor receptor (EGFR) with high specificity. It was demonstrated that h-R3 has a unique clinical profile for immunotherapy of adult gliomas and pediatric pontine gliomas. The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGER.
    Permanent Link: http://hdl.handle.net/11104/0207407

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.